Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High – What’s Next?

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $30.43 and last traded at $29.94, with a volume of 236913 shares trading hands. The stock had previously closed at $28.75.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ELVN shares. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Stock Performance

The stock has a market capitalization of $1.75 billion, a P/E ratio of -15.75 and a beta of 0.33. The company’s 50-day moving average price is $25.05 and its 200 day moving average price is $21.79.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). Analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,230 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at $592,898.46. The trade was a 5.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $29.04, for a total value of $145,200.00. Following the transaction, the insider owned 740,188 shares of the company’s stock, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 233,843 shares of company stock worth $6,145,489 in the last 90 days. 25.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

A number of large investors have recently added to or reduced their stakes in ELVN. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares during the last quarter. Invesco Ltd. raised its stake in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Swiss National Bank grew its stake in shares of Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after buying an additional 1,100 shares in the last quarter. Finally, Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.